Last reviewed · How we verify
long-lasting injectable naltrexone
long-lasting injectable naltrexone is a Opioid receptor antagonist Small molecule drug developed by State University of New York - Upstate Medical University. It is currently FDA-approved for Opioid use disorder (prevention of relapse), Alcohol use disorder.
Naltrexone is an opioid receptor antagonist that blocks the effects of opioids and reduces cravings for opioid use.
Naltrexone is an opioid receptor antagonist that blocks the effects of opioids and reduces cravings for opioid use. Used for Opioid use disorder (prevention of relapse), Alcohol use disorder.
At a glance
| Generic name | long-lasting injectable naltrexone |
|---|---|
| Sponsor | State University of New York - Upstate Medical University |
| Drug class | Opioid receptor antagonist |
| Target | Opioid receptors (mu, delta, kappa) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Naltrexone competitively binds to opioid receptors (mu, delta, and kappa) in the central nervous system, preventing opioid agonists from activating these receptors. The long-acting injectable formulation provides sustained drug levels over weeks to months, improving medication adherence and reducing relapse risk in opioid use disorder by maintaining continuous receptor blockade.
Approved indications
- Opioid use disorder (prevention of relapse)
- Alcohol use disorder
Common side effects
- Injection site reactions
- Nausea
- Headache
- Fatigue
- Hepatotoxicity (at high doses)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- long-lasting injectable naltrexone CI brief — competitive landscape report
- long-lasting injectable naltrexone updates RSS · CI watch RSS
- State University of New York - Upstate Medical University portfolio CI
Frequently asked questions about long-lasting injectable naltrexone
What is long-lasting injectable naltrexone?
How does long-lasting injectable naltrexone work?
What is long-lasting injectable naltrexone used for?
Who makes long-lasting injectable naltrexone?
What drug class is long-lasting injectable naltrexone in?
What development phase is long-lasting injectable naltrexone in?
What are the side effects of long-lasting injectable naltrexone?
What does long-lasting injectable naltrexone target?
Related
- Drug class: All Opioid receptor antagonist drugs
- Target: All drugs targeting Opioid receptors (mu, delta, kappa)
- Manufacturer: State University of New York - Upstate Medical University — full pipeline
- Therapeutic area: All drugs in Psychiatry / Addiction Medicine
- Indication: Drugs for Opioid use disorder (prevention of relapse)
- Indication: Drugs for Alcohol use disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing